Abstract
Injecting drug use is the main risk of hepatitis C virus (HCV) transmission in most developed countries. HCV antiviral treatment (peginterferon-a + ribavirin) has been shown to be cost-effective for patients with no reinfection risk. We examined the cost-effectiveness of providing antiviral treatment for injecting drug users (IDUs) as compared with treating ex/non-IDUs or no treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 49-57 |
| Number of pages | 9 |
| Journal | Hepatology |
| Volume | 55 |
| Issue number | 1 |
| Early online date | 6 Dec 2011 |
| DOIs | |
| Publication status | Published - Jan 2012 |
Keywords
- hepatitis C
- antiviral treatment
- intravenous drug users
- reinfection risk
Fingerprint Dive into the research topics of 'Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations'. Together they form a unique fingerprint.
Cite this
Martin, N. K., Vickerman, P., Miners, A., Foster, G. R., Hutchinson, S., Goldberg, D., & Hickman, M. (2012). Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology, 55(1), 49-57. https://doi.org/10.1002/hep.24656